Login / Signup

Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials.

Poorva BindalMimi NajjarKelly KoehnAmandeep GodaraDouglas W SborovBrian McCluneKelley JulianCharlotte WagnerGhulam Rehman Mohyuddin
Published in: Leukemia & lymphoma (2023)
Keyphrases
  • double blind
  • open label
  • placebo controlled
  • phase iii
  • multiple myeloma
  • newly diagnosed
  • phase ii
  • stem cells
  • mesenchymal stem cells
  • study protocol
  • cell therapy